Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BOLT Bolt Biotherapeutics	$0.31 +4.2%	$0.35	$0.28 ▼ $0.80	$12.04M	0.96	195,877 shs	554,331 shs
CRIS Curis	$2.25 +7.7%	$1.79	$1.02 ▼ $10.99	$23.54M	3.65	71,260 shs	134,543 shs
MTEM Molecular Templates		$0.00	$0.00 ▼ $1.59	$1K	1.53	4.63 million shs	N/A
SABS SAB Biotherapeutics	$1.81 +2.8%	$1.55	$1.00 ▼ $5.01	$16.82M	0.47	66,534 shs	38,746 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BOLT Bolt Biotherapeutics	+4.18%	-3.38%	-13.97%	-33.83%	-58.68%
CRIS Curis	+7.66%	+13.07%	+24.31%	-25.00%	-78.77%
MTEM Molecular Templates	0.00%	0.00%	0.00%	-80.00%	-99.99%
SABS SAB Biotherapeutics	+2.84%	-2.69%	+9.37%	+5.85%	-35.82%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BOLT Bolt Biotherapeutics	3.4075 of 5 stars	3.2	4.0	0.0	0.0	2.7	3.3	1.3
CRIS Curis	3.0869 of 5 stars	3.5	5.0	0.0	0.0	2.8	0.0	1.3
MTEM Molecular Templates	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SABS SAB Biotherapeutics	3.6588 of 5 stars	3.5	5.0	0.0	0.0	3.6	1.7	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BOLT Bolt Biotherapeutics	2.33	Hold	$2.50	696.18% Upside
CRIS Curis	3.00	Buy	$17.00	655.56% Upside
MTEM Molecular Templates	0.00	N/A	N/A	N/A
SABS SAB Biotherapeutics	3.00	Buy	$12.20	574.03% Upside

Current Analyst Ratings Breakdown

Latest BOLT, CRIS, SABS, and MTEM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/20/2025	BOLT Bolt Biotherapeutics	Lake Street Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$4.00
5/19/2025	CRIS Curis	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy	$17.00
5/15/2025	SABS SAB Biotherapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $20.00
5/14/2025	SABS SAB Biotherapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$10.00
5/13/2025	BOLT Bolt Biotherapeutics	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Hold ➝ Hold	$1.25 ➝ $1.00
4/1/2025	SABS SAB Biotherapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$25.00 ➝ $20.00
4/1/2025	SABS SAB Biotherapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.00 ➝ $6.00
3/31/2025	CRIS Curis	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$20.00 ➝ $16.00
3/25/2025	BOLT Bolt Biotherapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral
3/25/2025	BOLT Bolt Biotherapeutics	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Hold ➝ Hold	$1.50 ➝ $1.25

(Data available from 5/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BOLT Bolt Biotherapeutics	$3.64M	3.31	N/A	N/A	$2.97 per share	0.11
CRIS Curis	$11.20M	2.10	N/A	N/A	$3.34 per share	0.67
MTEM Molecular Templates	$23.48M	0.00	N/A	N/A	$0.78 per share	0.00
SABS SAB Biotherapeutics	$2.24M	7.51	N/A	N/A	$6.21 per share	0.29

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BOLT Bolt Biotherapeutics	-$69.20M	-$1.67	N/A	N/A	N/A	-665.56%	-69.46%	-48.55%	8/12/2025 (Estimated)
CRIS Curis	-$47.41M	-$6.23	N/A	N/A	N/A	-443.35%	-923.37%	-78.35%	8/7/2025 (Estimated)
MTEM Molecular Templates	-$8.12M	-$2.70	N/A	N/A	N/A	-61.35%	-260.50%	-46.90%	N/A
SABS SAB Biotherapeutics	-$42.19M	-$3.70	N/A	N/A	N/A	-1,450.14%	-94.37%	-67.26%	8/14/2025 (Estimated)

Latest BOLT, CRIS, SABS, and MTEM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/12/2025	Q1 2025	BOLT Bolt Biotherapeutics	-$0.34	-$0.29	+$0.05	-$0.29	$0.77 million	$1.22 million
5/9/2025	Q1 2025	SABS SAB Biotherapeutics	-$1.00	-$0.56	+$0.44	-$0.56	$0.13 million	N/A
5/6/2025	Q1 2025	CRIS Curis	-$1.14	-$1.25	-$0.11	-$1.25	$2.37 million	$2.38 million
3/31/2025	Q4 2024	CRIS Curis	-$1.36	-$1.25	+$0.11	-$1.25	$2.04 million	$2.70 million
3/28/2025	Q4 2024	SABS SAB Biotherapeutics	-$1.16	-$1.23	-$0.07	-$1.23	$0.12 million	$0.05 million
3/24/2025	Q4 2024	BOLT Bolt Biotherapeutics	-$0.38	-$0.38	N/A	-$0.42	$0.79 million	$0.01 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BOLT Bolt Biotherapeutics	$0.36	114.65%	N/A	N/A	N/A
CRIS Curis	N/A	N/A	N/A	N/A	N/A
MTEM Molecular Templates	N/A	N/A	N/A	N/A	N/A
SABS SAB Biotherapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BOLT Bolt Biotherapeutics	0.21	3.16	3.16
CRIS Curis	N/A	1.22	1.22
MTEM Molecular Templates	N/A	1.56	1.56
SABS SAB Biotherapeutics	0.09	3.69	3.69

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BOLT Bolt Biotherapeutics	86.70%
CRIS Curis	29.97%
MTEM Molecular Templates	95.47%
SABS SAB Biotherapeutics	7.82%

Insider Ownership

Company	Insider Ownership
BOLT Bolt Biotherapeutics	30.90%
CRIS Curis	5.45%
MTEM Molecular Templates	13.90%
SABS SAB Biotherapeutics	26.46%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BOLT Bolt Biotherapeutics	90	38.34 million	26.45 million	Not Optionable
CRIS Curis	60	10.46 million	7.98 million	No Data
MTEM Molecular Templates	260	6.58 million	5.67 million	No Data
SABS SAB Biotherapeutics	140	9.29 million	6.79 million	Not Optionable

BOLT, CRIS, SABS, and MTEM Headlines

Recent News About These Companies

SAB Biotherapeutics, Inc.: SAB BIO Announces Q1 2025 Financial Results and Provides Company Updates

May 9, 2025 | finanznachrichten.de

SAB BIO Announces Q1 2025 Financial Results and Provides Company Updates

May 9, 2025 | globenewswire.com

Craig-Hallum Reaffirms Their Buy Rating on SAB Biotherapeutics (SABS)

April 3, 2025 | markets.businessinsider.com

SAB Biotherapeutics, Inc.: SAB BIO Reports Full Year 2024 Operating and Financial Results

April 2, 2025 | finanznachrichten.de

SAB Biotherapeutics price target lowered to $20 from $25 at Chardan

April 2, 2025 | markets.businessinsider.com

SAB Biotherapeutics held cash and equivalents of $20.8 million at end of 2024

March 31, 2025 | markets.businessinsider.com

SAB BIO Reports Full Year 2024 Operating and Financial Results

March 31, 2025 | globenewswire.com

SAB BIO to Participate in Upcoming Investor Conferences

January 31, 2025 | globenewswire.com

Strong Buy Recommendation for SAB-142: Promising Phase 1 Results and Future Market Potential in T1D Treatment

January 29, 2025 | markets.businessinsider.com

SAB Biotherapeutics, Inc.: SAB BIO Announces Positive Topline Phase 1 Clinical Results with Potentially Disease-Modifying T1D Therapy SAB-142

January 29, 2025 | finanznachrichten.de

SAB BIO Announces Positive Topline Phase 1 Clinical Results with Potentially Disease-Modifying T1D Therapy SAB-142

January 28, 2025 | globenewswire.com

SAB Biotherapeutics (SABS) Gets a Buy from Craig-Hallum

January 25, 2025 | markets.businessinsider.com

SAB BIO Announces R&D Webinar Event to Review Phase 1 Topline Results for SAB-142, a Disease-Modifying T1D Therapy

January 23, 2025 | globenewswire.com

Here’s Why SAB Biotherapeutics, Inc. (NASDAQ:SABS) Is Among the Best Diabetes Stocks to Buy Under $10

January 6, 2025 | insidermonkey.com

SAB Biotherapeutics Leads The Pack Of 3 US Penny Stocks To Consider

December 23, 2024 | finance.yahoo.com

SAB Biotherapeutics Third Quarter 2024 Earnings: US$1.12 loss per share (vs US$0.97 loss in 3Q 2023)

November 9, 2024 | finance.yahoo.com

Promising Outlook for SAB Biotherapeutics’ SAB-142 in Type 1 Diabetes Treatment Drives Buy Rating

November 7, 2024 | markets.businessinsider.com

SAB BIO Announces Third Quarter 2024 Financial Results and Provides Company Update

November 6, 2024 | globenewswire.com

Craig-Hallum Remains a Buy on SAB Biotherapeutics (SABS)

October 15, 2024 | markets.businessinsider.com

Craig-Hallum Initiates Coverage of SAB Biotherapeutics (SABS) with Buy Recommendation

October 10, 2024 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BOLT, CRIS, SABS, and MTEM Company Descriptions

Bolt Biotherapeutics NASDAQ:BOLT

$0.31 +0.01 (+4.18%)

Closing price 05/29/2025 04:00 PM Eastern

Extended Trading

$0.31 -0.01 (-1.59%)

As of 05/29/2025 06:26 PM Eastern

Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company's lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer. It is also developing BDC-3042, an agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer. The company has collaboration agreements with Toray Industries, Genmab A/S, Innovent Biologics, Inc., Bristol-Myers Squibb, and F. Hoffmann-La Roche Ltd; and license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.

Curis NASDAQ:CRIS

$2.25 +0.16 (+7.66%)

Closing price 05/29/2025 04:00 PM Eastern

Extended Trading

$2.17 -0.08 (-3.33%)

As of 05/29/2025 07:28 PM Eastern

Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral, small molecule antagonist designated as CA-170 that selectively targets PD-L1 and VISTA; and CA-327, an oral, small molecule, TIM3/PD-L1, which is a molecule antagonist of PD-L1 and TIM3. It has collaboration agreement with Genentech Inc., or Genentech and F. Hoffmann-La Roche Ltd, or Roche, for the commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway antagonist for the treatment of advanced basal cell carcinoma, or BCC; Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and also licensed four programs under the Aurigene collaboration, including emavusertib. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.

Molecular Templates NASDAQ:MTEM

Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases in the United States. The company develops therapies through its proprietary biologic drug platform technology (ETB). It is also developing MT- 8421, an ETB candidate that is in Phase I clinical trial for the treatment of dismantling TME through direct cell-kill of tumor and immune cell; MT-0169, which is in Phase I clinical trial to treat relapsed/refractory multiple myeloma; and MT-6402 in that is in Phase I clinical trial for relapsed/refractory patients with PD-L1 expressing tumors. The company has a collaboration agreement with Bristol Myers Squibb to discover and develop novel products containing ETBs directed to multiple targets. Molecular Templates, Inc. was founded in 2001 and is headquartered in Austin, Texas.

SAB Biotherapeutics NASDAQ:SABS

$1.81 +0.05 (+2.84%)

Closing price 05/29/2025 04:00 PM Eastern

Extended Trading

$1.82 +0.01 (+0.50%)

As of 05/29/2025 07:49 PM Eastern

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases. The company also uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors or plasma. In addition, its lead product candidate SAB-142, a human, multi-target anti-thymocyte globulin treatment, currently under Phase 1 trials in delaying the onset or progression of type 1 diabetes. Further, the company develops SAB-176, a multivalent, broadly neutralizing - human polyclonal immunoglobulin therapeutic candidate, currently in Phase 2a development for the treatment or prevention of severe influenza. SAB Biotherapeutics, Inc. was founded in 2014 and is headquartered in Miami Beach, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time